Search Results
Your search for ,sIX matches 2897 pages
Showing 2801 - 2850Same Progression-Free Survival, Better Quality of Life With Lower-Dose Weekly vs Every-3-Week Carboplatin/Paclitaxel in Advanced Ovarian Cancer
In an open-label phase III trial (MITO-7) reported in The Lancet Oncology, Pignata et al found that while a lower-dose weekly carboplatin/paclitaxel regimen did not improve progression-free survival compared with standard every-3-week carboplatin/paclitaxel as first-line treatment of advanced...
Early Palliative Care Benefits Patients With Advanced Cancer
In a study published in The Lancet, Zimmermann et al compared quality of life, symptom severity, and care satisfaction with early initiation of palliative care vs standard cancer care in patients with advanced cancer. Although early palliative care was not associated with improved quality of life...
Reduced Risk of Cervical Lesions Among Girls and Women 6 Years After Licensure of HPV Vaccine in Denmark
In a cohort study reported in the Journal of the National Cancer Institute, Baldur-Felskov et al found that there has been a significant reduction in cervical lesions among Danish girls and women receiving the quadrivalent human papillomavirus (HPV) vaccine during the first 6 years of its...
Bevacizumab Added to Radiotherapy/Temozolomide Improves Progression-Free Survival but Not Overall Survival in Newly Diagnosed Glioblastoma
In a double-blind phase III trial reported in The New England Journal of Medicine, Chinot et al assessed adding bevacizumab (Avastin) to radiotherapy and temozolomide in patients with newly diagnosed glioblastoma. This was the second of two similar studies published in the February 20 issue of...
Use of Intravenous Pegaspargase in Adapted Pediatric Regimen Is Feasible in Adults With Newly Diagnosed ALL
Asparaginase treatment, standard in pediatric acute lymphoblastic leukemia (ALL) regimens, is excluded or used for shorter durations in treatment of adults with ALL due to risk of toxicity. In a study reported in Journal of Clinical Oncology, Douer et al evaluated a pegaspargase (Oncaspar) dosing...
Rituximab Active in Nodular Lymphocyte–Predominant Hodgkin Lymphoma
Mature results of a phase II study reported in the Journal of Clinical Oncology by Advani et al indicate that rituximab (Rituxan) is active in nodular lymphocyte–predominant Hodgkin lymphoma, which is characterized by expression of CD20 by malignant cells. Most patients relapsed, but durable...
No Mortality Benefit of Mammography Screening in 25-Year Follow-up of Canadian National Breast Screening Study
As reported in BMJ by Miller et al, the 25-year follow-up of the Canadian National Breast Screening Study has shown no mortality benefit of annual mammography screening for breast cancer compared with physical examination or usual care. Mammography screening was associated with...
Small Panel of FISH Cytogenetic Markers Distinguishes Risk in Medulloblastoma Subgroups
Among the four major molecular subgroups of medulloblastoma, WNT tumors are associated with excellent prognosis, whereas SHH and Group 4 tumors are associated with intermediate and Group 3 tumors with poor prognosis. In a study reported in the Journal of Clinical Oncology, Shih et al identified a...
Radiotherapy for Bulky Disease Added to R-CHOP Improves Outcome in Elderly Patients With Aggressive B-Cell Lymphoma
In an analysis reported in the Journal of Clinical Oncology, Held et al studied elderly patients with aggressive B-cell non-Hodgkin lymphoma and bulky disease in the most effective treatment arm of the RICOVER-60 trial, which included radiotherapy. The investigators compared outcomes ...
Cytoreductive Nephrectomy Improves Survival in Metastatic Renal Cell Carcinoma Patients With Longer Life Expectancy
Prior to the advent of targeted therapy, cytoreductive nephrectomy was associated with a 6-month improvement in overall survival in metastatic renal cell carcinoma. With the development of new and better targeted therapies for metastatic renal cell carcinoma, the appropriate use of cytoreductive...
Enzalutamide Improves Survival in Chemotherapy-Naive Metastatic Castration-Resistant Prostate Cancer
Enzalutamide (Xtandi) improved survival by 29% in men with chemotherapy-naive metastatic castration-resistant prostate cancer and reduced the risk of radiographic progression by 81%, according to complete results of the randomized, double-blind, placebo-controlled, multinational, phase III PREVAIL...
Dermoscopy Shows Characteristics of Cutaneous Metastases of Visceral Cancers
In a case series reported in JAMA Dermatology, Chernoff et al found that dermoscopic identification of vascular structures in cutaneous nodules in patients with known cancer diagnosis should raise suspicion for cutaneous metastasis. Study Details In the study, high-quality dermoscopic images of...
Afatinib Improves Progression-Free Survival vs Cisplatin/Gemcitabine in First-Line Treatment of Asian Patients With Advanced EGFR-Mutant NSCLC
Afatinib (Gilotrif) improves progression-free survival compared with pemetrexed (Alimta)/cisplatin in first-line treatment of patients with EGFR mutation–positive advanced non–small cell lung cancer (NSCLC). In the phase III LUX-Lung 6 trial reported in The Lancet Oncology, Wu ...
Pilot Study Shows Promise of Neoadjuvant Chemotherapy Without Routine Radiotherapy in Patients With Locally Advanced Rectal Cancer
Neoadjuvant chemoradiotherapy delays administration of optimal chemotherapy in stage II to III rectal cancer. In a pilot study reported in the Journal of Clinical Oncology, Schrag et al assessed outcomes with neoadjuvant FOLFOX (fluorouracil, leucovorin, oxaliplatin)/bevacizumab (Avastin) with...
Maintenance Capecitabine/Bevacizumab Delays Disease Progression in Metastatic Colorectal Cancer and Extends Survival in Subgroups
According to the final results of the phase III CAIRO3 trial by the Dutch Colorectal Cancer Group, maintenance treatment with capecitabine plus bevacizumab (Avastin) significantly delayed progression compared to observation in patients with metastatic colorectal cancer, and in a subset of patients, ...
Seven-Gene Score Incorporating Methylation and Expression Distinguishes AML Risk Groups
In a study reported in the Journal of Clinical Oncology, Marcucci et al assessed whether including epigenetic changes—ie, DNA methylation—as molecular risk factors could improve risk stratification in acute myeloid leukemia (AML). They found that a seven-gene score integrating DNA...
Irinotecan Drug-Eluting Beads Improve Outcomes in Colorectal Cancer Patients With Liver Metastases
Irinotecan drug-eluting beads given simultaneously with FOLFOX (leucovorin, fluorouracil, oxaliplatin) and bevacizumab (Avastin) in patients with unresectable liver metastasis from colorectal cancer improved response rates, increased resectability and prolonged hepatic progression-free survival in...
Surgeon Experience Affects Likelihood of Sentinel Lymph Node Biopsy in Older Women With Breast Cancer
Sentinel lymph node biopsy is standard of care for axillary staging in clinically node-negative breast cancer, and underuse of sentinel lymph node biopsy could be associated with unnecessary axillary lymph node dissection and lymphedema. In a study reported in JAMA Surgery, Yen et al assessed the...
Immunotherapy Strategy Boosts Survival in Metastatic Pancreatic Cancer
Overall survival was improved in patients with metastatic pancreatic cancer through an innovative immunotherapy strategy in a multicenter study to be reported at the 2014 Gastrointestinal Cancers Symposium (Abstract 177). The results were announced at a press briefing prior to the meeting....
Superior Progression-Free Survival With Obinutuzumab/Chlorambucil vs Rituximab/Chlorambucil in Previously Untreated CLL With Coexisting Conditions
Obinutuzumab (Gazyva) is a glycoengineered type 2 anti-CD20 antibody that appears to exhibit increased activity against chronic lymphocytic leukemia cells (CLL), with increased antibody-dependent cellular cytotoxicity and reduced complement-dependent cytotoxicity, compared with rituximab (Rituxan). ...
Anti–PD-1 Antibody Pidilizumab Plus Rituximab Shows High Activity in Relapsed Follicular Lymphoma
Antitumor immune responses may be inhibited by immune checkpoints in the tumor microenvironment including effects of PD-1 (programmed cell death 1), a co-inhibitory receptor on tumor T cells that impairs T-cell function. In a phase II study reported in The Lancet Oncology, Westin et al assessed the ...
Survival Benefit With High-Dose Cytarabine Induction in AML Patients Aged < 46 Years
In a European Organisation for Research and Treatment of Cancer (EORTC) and Gruppo Italiano Malattie Ematologiche dell’ Adulto (GIMEMA) phase III trial (AML-12) reported in Journal of Clinical Oncology, Willemze et al compared induction regimens containing high-dose or standard-dose...
Fractionated 90Y-Ibritumomab Tiuxetan Radioimmunotherapy Produces High Response Rate in Initial Therapy for Follicular Lymphoma
In a phase II trial reported in the Journal of Clinical Oncology, Illidge et al evaluated radioimmunotherapy with fractionated 90Y-ibritumomab tiuxetan (Zevalin) as initial treatment in patients with mostly advanced follicular lymphoma. The treatment was well tolerated, with manageable...
Less Is More: Postoperative Radiation May Be Avoided in Older Women With Estrogen Receptor–Rich Tumors
Among older women with hormone receptor–positive breast cancer, it is reasonable to omit whole-breast radiation therapy after breast-conserving surgery and neoadjuvant hormone therapy if the patient’s tumors have high levels of estrogen receptor expression, but radiation should remain...
ASH 2013: Brentuximab Vedotin Shows Promising Activity in Non-Hodgkin Lymphoma
The antibody-drug conjugate brentuximab vedotin (Adcetris) has shown “compelling” antitumor activity in patients with non-Hodgkin lymphomas who were no longer responding to treatment, in a study presented at the American Society of Hematology (ASH) Annual Meeting and Exposition...
Novel Agents IPI-145 and ABT-199 Show Encouraging Results in Phase I CLL Studies
Two novel agents—the small-molecule PI3K inhibitor IPI-145 and the Bcl-2 inhibitor ABT-199—show promising activity in chronic lymphocytic leukemia (CLL), according to two phase I studies presented at the 55th American Society of Hematology (ASH) Annual Meeting and Exposition (Abstracts...
Obinutuzumab/Chlorambucil Superior to Rituximab/Chlorambucil as First-Line Treatment for Older CLL Patients With Comorbidities
Obinutuzumab (Gazyva) plus chlorambucil (Leukeran) was superior to rituximab (Rituximab) plus chlorambucil as first-line therapy in older chronic lymphocytic leukemia (CLL) patients with comorbidities, with an acceptable safety profile, according to final results of the phase III CLL11 trial....
Successful Chimeric Antigen Receptor–Expressing T-Cell Treatment Reported in Advanced Lymphomas
Development of autologous genetically engineered anti-CD19 chimeric antigen receptor (CAR)-expressing T cells holds promise in the treatment of hematologic malignancies. CAR T cells are being studied in adult and pediatric acute lymphocytic leukemias and in chronic lymphocytic leukemia, and...
Digital Breast Tomosynthesis Increases Cancer Detection and Reduces Recall Rates
Compared to traditional mammography, three-dimensional (3D) mammography—known as digital breast tomosynthesis—found 22% more breast cancers and led to fewer call-backs in a large screening study at the Hospital of the University of Pennsylvania, researchers reported today at the 99th...
Disease-Free Survival Is Acceptable Surrogate for Overall Survival in Trials of Adjuvant Chemotherapy for Gastric Cancers
Disease-free survival is an acceptable surrogate for overall survival in trials of cytotoxic agents for gastric cancer in the adjuvant setting, the GASTRIC group concluded after conducting a meta-analysis of data from 3,288 individual patients enrolled in 14 randomized clinical trials. The trials...
Epigenetic Modification of HAND2 May Be Associated With the Development of Endometrial Cancer
In a study reported in the journal PLoS One, Allison Jones, MD, of the Elizabeth Garrett Anderson Institute for Women’s Health, University College London, and colleagues analyzed the functional role of epigenetic factors in endometrial cancer development. They found that HAND2 methylation...
Brentuximab Vedotin Plus ABVD or AVD Is Highly Active in Newly Diagnosed Hodgkin Lymphoma
Brentuximab vedotin (Adcetris) is active in patients with relapsed/refractory Hodgkin’s lymphoma. In a phase I study reported in The Lancet Oncology, Anas Younes, MD, of Memorial Sloan-Kettering Cancer Center (formerly of The University of Texas MD Anderson Cancer Center), and colleagues...
MicroRNA Signature Predicts Risk of Recurrence After Surgery for Stage II Colon Cancer
In a study reported in The Lancet Oncology, Jia-Xing Zhang, MD, of Sun Yat-sen University, and colleagues identified a six-microRNA (miRNA) signature that predicted risk of recurrence after surgery for stage II colon cancer and that may help to identify patients most likely to benefit from adjuvant ...
International Ki67 Reproducibility Study Shows High Intralaboratory but Only Moderate Interlaboratory Reproducibility
In a study reported in Journal of the National Cancer Institute, Mei-Yin C. Polley, PhD, of the National Cancer Institute, and colleagues assessed intralaboratory and interlaboratory variability in Ki67 scoring. They found high intralaboratory reproducibility but only moderate interlaboratory...
Pegfilgrastim Prophylaxis Throughout Chemotherapy Is More Effective in Preventing Febrile Neutropenia in Breast Cancer (and More Costly)
Available data suggest that risk of febrile neutropenia is greatest during the first two cycles of chemotherapy in patients with breast cancer. In a study reported in the Journal of Clinical Oncology, Maureen J. Aarts of Maastricht University Medical Centre in the Netherlands, and colleagues...
Vemurafenib Produces Rapid Responses in Hairy Cell Leukemia
Preliminary results of an ongoing clinical trial suggest that the BRAF inhibitor vemurafenib (Zelboraf)—indicated for the treatment of metastatic melanoma with BRAF V600E mutation—may have an important role in the treatment of hairy cell leukemia. The cornerstone of therapy for this...
Early Autologous Transplantation Improves Progression-Free Survival in Aggressive Non-Hodgkin Lymphoma
The strategy of autologous stem cell transplantation as consolidation in high-intermediate– or high-risk diffuse aggressive non-Hodgkin lymphoma (NHL) has not been specifically examined in the rituximab (Rituxan) era. In a phase III trial (Southwest Oncology Group 9704) reported in The New...
Dose-Limiting Late Toxicity Observed After Hypofractionated Dose-Escalated Radiotherapy in NSCLC
In a phase I study reported in Journal of Clinical Oncology, Donald M. Cannon, MD, of University of Wisconsin School of Medicine and Public Health and Mountain States Tumor Institute, and colleagues attempted to identify the maximum tolerated dose of dose-escalated hypofractionated radiation...
Perioperative FOLFOX4 Does Not Improve Overall Survival vs Surgery Alone in Patients With Resectable Liver Metastases From Colorectal Cancer
Previously reported results of the phase III EORTC intergroup 40983 trial showed that perioperative chemotherapy with FOLFOX4 (leucovorin, fluorouracil [5-FU], and oxaliplatin) increased progression-free survival compared with surgery alone in patients with initially resectable liver metastases...
New Biomarker May Help Guide Treatment of Melanoma Patients
A functional biomarker that can predict whether BRAF-mutant melanomas respond to drugs targeting BRAF could help guide the treatment of patients with these cancers, according to results presented at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics, held...
Association Between Prevalence of Symptoms and Impaired Health-Related Quality of Life in Adult Survivors of Childhood Cancer
In a study reported in the Journal of Clinical Oncology, I-Chan Huang, PhD, of University of Florida at Gainesville, and colleagues investigated the association between prevalence of symptoms and health-related quality of life in adult survivors of childhood cancer enrolled in the St. Jude...
Improved Progression-Free but Not Overall Survival With Addition of Maintenance Erlotinib to Bevacizumab After Chemotherapy Plus Bevacizumab in NSCLC
In the phase IIIB ATLAS trial reported in the Journal of Clinical Oncology, Bruce E. Johnson, MD, of Dana-Farber Cancer Institute, and colleagues assessed the addition of maintenance erlotinib (Tarceva) to bevacizumab (Avastin) following chemotherapy plus bevacizumab in first-line treatment of ...
Most Common Tumors Are Driven by Two to Six DNA Mutations
A genetic analysis of 3,281 tumors from 12 cancer types, including breast, lung, endometrial, glioblastoma multiforme, ovarian, colon, and acute myeloid leukemia, has found 127 significantly mutated genes that appear to be involved in either cancer initiation or progression. Although the average...
Simple Blood Test May Diagnose Lung and Other Cancers
A simple blood test that measures serum free fatty acids and their metabolites may detect early-stage lung cancer and its recurrence, according to a study from The Cleveland Clinic presented at the ANESTHESIOLOGY™ 2013 Annual Meeting in San Francisco (Abstract A4267). The study was presented ...
ASCO and the College of American Pathologists Issue Updated Guideline on HER2 Testing in Breast Cancer
ASCO and the College of American Pathologists (CAP) today issued a joint, updated guideline to improve the accuracy and reporting of human epidermal growth factor receptor 2 (HER2) testing in patients with invasive breast cancer. The six-recommendation guideline is based on a systematic review of...
Men With Advanced Prostate Cancer Worry More About Burdening Family and Friends Than Dying, Survey Finds
Men with advanced prostate cancer are now living longer than ever, and it is estimated that one in six U.S. men will be diagnosed with prostate cancer in their lifetime. However, little research has been conducted to understand the psychosocial needs of these men and their caregivers after...
Repurposed Antidepressants May Have Potential to Treat Small Cell Lung Cancer
A bioinformatics approach to repurposing drugs resulted in identification of a class of antidepressants as a potential new treatment for small cell lung cancer, according to a study published in Cancer Discovery. Based on data generated using bioinformatics, two drugs approved by the U.S. Food and ...
Phase II Study Shows Activity of Selective Aurora A Kinase Inhibitor Alisertib in Relapsed/Refractory Aggressive B- and T-Cell Non-Hodgkin Lymphoma
Aurora A kinase is overexpressed in aggressive lymphomas and may correlate with more histologically aggressive forms of disease. In a phase II study reported in Journal of Clinical Oncology, Jonathan W. Friedberg, MD, of University of Rochester Wilmot Cancer Center, and colleagues assessed the...
ASTRO: Younger Adults With a Limited Number of Brain Metastases Have Improved Overall Survival After Stereotactic Radiosurgery Alone
When treated with stereotactic radiosurgery that is not combined with whole-brain radiotherapy, adult brain cancer patients who were 50 years old and younger were found to have improved survival, according to research presented on Sunday, September 22, at the American Society for Radiation...
ASTRO: Proton Therapy Yields Encouraging Outcomes for Pediatric Brain Tumor Patients
When used to treat pediatric patients with intracranial malignant tumors, proton therapy may limit the toxicity of radiation therapy while preserving tumor control, according to research presented on Sunday, September 22, at the American Society for Radiation Oncology’s 55th Annual Meeting...
